Yuan J Cheng

US Patent:

20130018064, Jan 17, 2013

Filed:

Nov 19, 2010

Appl. No.:

13/511360

Inventors:

Nick A. Paras - San Francisco CA, US
Yuan Cheng - Newbury Park CA, US
Timothy Powers - Malibu CA, US
James Brown - Moorpark CA, US
Stephen A. Hitchcock - Jupiter FL, US
Ted Judd - Simi Valley CA, US
Patricia Lopez - West Hills CA, US
Qiufen Xue - Newbury Park CA, US
Bryant Yang - Simi Valley CA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

A61K 31/506
A61P 25/28
A61K 31/4709
C07D 401/08
C07D 401/06

US Classification:

514269, 544333, 514256, 546159, 514313, 544319

Abstract:

The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I, wherein ring A, B, B, B, L, R, R, ring Z, m and p of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease (AD), cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.

US Patent:

20130040931, Feb 14, 2013

Filed:

Jan 14, 2011

Appl. No.:

13/522823

Inventors:

Nick A. Paras - San Francisco CA, US
James Brown - Moorpark CA, US
Yuan Cheng - Newbury Park CA, US
Stephen A. Hitchcock - Jupiter FL, US
Ted Judd - Granada Hills CA, US
Patricia Lopez - West Hills CA, US
Ana Elena Minatti - Santa Monica CA, US
Thomas Nixey - Newbury Park CA, US
Timothy Powers - Malibu CA, US
Christopher M. Tegley - Thousand Oaks CA, US
Qiufen Xue - Newbury Park CA, US
Bryant Yang - Simi Valley CA, US
Wenge Zhong - Thousands Oaks CA, US

Assignee:

Amgen Inc. - Thousand Oaks CA

International Classification:

A61K 31/5377
C07D 413/04
C07D 471/04
A61P 25/16
A61K 31/4709
C07D 417/14
A61P 25/28
A61P 25/00
C07D 413/14
C07D 405/14

US Classification:

51421018, 544128, 5142352, 544127, 5142332, 544122, 546159, 514313, 544120, 5142345, 544 80, 5142325, 5142308

Abstract:

The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula (I); wherein ring A, B, B, B, L, R, R, ring Z, m and n of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease (AD), cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula (I), intermediates and processes useful for the preparation of compounds of Formula (I).

US Patent:

20230078200, Mar 16, 2023

Filed:

Dec 8, 2020

Appl. No.:

17/783232

Inventors:

- Thousand Oaks CA, US
Michael OLLMANN - San Carlos CA, US
Oliver HOMANN - Berkeley CA, US
Yuan CHENG - Newbury Park CA, US

Assignee:

AMGEN INC. - Thousand Oaks CA

International Classification:

C12N 15/113
A61P 9/10

Abstract:

The present invention relates to RNAi constructs for reducing expression of the LPA gene, which encodes apolipoprotein(a), a component of lipoprotein(a) (Lp(a)) particles. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease, peripheral artery disease, stroke, and myocardial infarction, and to reduce serum Lp(a) levels are also described.